KRYS logo

KRYS
Krystal Biotech Inc

1,770
Mkt Cap
$8.03B
Volume
351,010.00
52W High
$298.30
52W Low
$122.80
PE Ratio
40.12
KRYS Fundamentals
Price
$266.90
Prev Close
$274.59
Open
$274.59
50D MA
$264.42
Beta
0.98
Avg. Volume
314,786.20
EPS (Annual)
$6.84
P/B
6.57
Rev/Employee
$1.32M
$6,565.67
Loading...
Loading...
News
all
press releases
Dino Rossi Sells 18,950 Shares of Krystal Biotech (NASDAQ:KRYS) Stock
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) Director Dino Rossi sold 18,950 shares of the business's stock in a transaction that occurred on Thursday, February 19th. The shares were sold at...
MarketBeat·17h ago
News Placeholder
More News
News Placeholder
Krystal Biotech (NASDAQ:KRYS) Director Sells $4,953,719.50 in Stock
Krystal Biotech, Inc. (NASDAQ:KRYS - Get Free Report) Director Dino Rossi sold 18,950 shares of the firm's stock in a transaction on Thursday, February 19th. The stock was sold at an average price of...
MarketBeat·1d ago
News Placeholder
Biotech Investor Adds $3 Million to Krystal Biotech as Revenue Hits $389 Million in 2025
Key PointsRedmile Group bought 16,317 shares of Krystal Biotech; the estimated trade size was $3.43 million based on average closing prices in the fourth quarter...
Nasdaq News: Markets·2d ago
News Placeholder
Krystal Biotech, Inc. $KRYS Shares Sold by Aberdeen Group plc
Aberdeen Group plc lessened its position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) by 45.3% in the third quarter, according to the company in its most recent Form 13F filing with the...
MarketBeat·5d ago
News Placeholder
Krystal Biotech (NASDAQ:KRYS) Trading Down 6.9% - Here's Why
Krystal Biotech (NASDAQ:KRYS) Stock Price Down 6.9% - Time to Sell...
MarketBeat·5d ago
News Placeholder
HC Wainwright Forecasts Krystal Biotech Q1 Earnings
Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) - Research analysts at HC Wainwright issued their Q1 2026 earnings per share estimates for shares of Krystal Biotech in a research note issued to...
MarketBeat·6d ago
News Placeholder
Krystal Biotech Q4 Earnings Beat Estimates, Revenues Miss Mark
KRYS beats Q4 estimates as Vyjuvek sales jump 17%. It secures 660+ U.S. reimbursements and advances the gene therapy pipeline into 2026.
Zacks·6d ago
News Placeholder
Krystal Biotech (NASDAQ:KRYS) Price Target Raised to $323.00
Chardan Capital upped their price objective on shares of Krystal Biotech from $220.00 to $323.00 and gave the stock a "buy" rating in a research report on Wednesday...
MarketBeat·7d ago
News Placeholder
Expert Outlook: Krystal Biotech Through The Eyes Of 9 Analysts
read more...
Benzinga·7d ago
News Placeholder
Stock Market News for Feb 18, 2026
U.S. stock markets closed higher on Tuesday. Stock prices were muted yesterday as major indexes were mostly sidetracked.
Zacks·7d ago
<
1
2
...
>

Latest KRYS News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.